ADMA BIOLOGICS INC - COMMON STOCK

ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management

18 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD

16 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update

08 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update

09 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

02 Aug 2023 07:00:02 By Nasdaq GlobeNewswire

ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

19 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update

10 May 2023 16:05:01 By Nasdaq GlobeNewswire

ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023

03 May 2023 07:00:01 By Nasdaq GlobeNewswire

ADMA Biologics Announces Amendment to Credit Agreement

02 May 2023 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

23 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

16 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

08 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance

17 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

13 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

09 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

07 Dec 2022 08:45:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Proposed Public Offering of Common Stock

06 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

06 Dec 2022 16:01:00 By Nasdaq GlobeNewswire